EGFR-TKI plus antiangiogenic agent combination therapy may reduce the incidence of EGFR-TKI-associated interstitial lung disease in Asian.
Tai-Huang LeeHsiao-Ling ChenMing-Ju TsaiChih-Jen YangPublished in: The Kaohsiung journal of medical sciences (2022)